New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 14, 2013
18:59 EDTAINV, XONE, VIPS, RMTI, VOXX, ATHX, TXCCOn The Fly: After Hours Movers
UP AFTER EARNINGS: Vipshop (VIPS), up 10%... TranSwitch (TXCC), up after earnings, hiring Needham to evaluate strategic alternatives... VOXX International (VOXX), up 7.3%. DOWN AFTER EARNINGS: ExOne (XONE), down 8.4%... Athersys (ATHX), down 5.6%. ALSO LOWER: Rockwell Medical (RMTI), down 10% after filing to sell an ungiven amount of common stock... Apollo Investment (AINV), down 3.5% after filing to sell 18M shares of common stock.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
January 30, 2015
06:02 EDTRMTIRockwell Medical initiated with a Buy at BofA/Merrill
Target $15.
January 29, 2015
10:51 EDTRMTIOptions with decreasing implied volatility
Subscribe for More Information
January 28, 2015
11:41 EDTRMTIRockwell Medical ends loan pact with Hercules Technology
Rockwell Medical disclosed in a regulatory filing that on December 19, the company voluntarily paid off and terminated its Loan and Security Agreement, dated as of June 14, 2013, with Hercules Technology. The payoff amount of $18,902,434.33 included principal, accrued and unpaid interest, fees, costs and expenses payable under the Loan Agreement, including an end of term charge of $1.1M In connection with such repayment, Hercules terminated its security interest in the assets of the company subject to the Loan Agreement. The early repayment was required by the company’s Exclusive Distribution Agreement, dated October , with Baxter Healthcare Corporation.
10:54 EDTXONEStratasys shares at 'compelling entry point' after pullback, says Canaccord
Subscribe for More Information
10:29 EDTRMTIOptions with decreasing implied volatility
Subscribe for More Information
January 27, 2015
10:35 EDTRMTIOptions with decreasing implied volatility
Subscribe for More Information
08:25 EDTRMTIRockwell Medical approval a 'significant positive,' says Summer Street
Subscribe for More Information
January 26, 2015
16:25 EDTRMTIFDA wanted second Rockwell study for ESA benfits, Bloomberg says
Subscribe for More Information
13:30 EDTRMTIRockwell Medical announces Triferic prescribing information
Rockwell Medical announced that Triferic is indicated for the replacement of iron to maintain hemoglobin in adult patients with hemodialysis-dependent chronic kidney disease. Triferic is not intended for use in patients receiving peritoneal dialysis and has not been studied in patients receiving home hemodialysis, the company added. The label will state, "Observe for signs and symptoms of hypersensitivity during and after hemodialysis and until clinically stable." The label does not include ESA sparing, as Brean Capital predicted earlier when reiterating its Sell rating on shares of Rockwell.
10:30 EDTRMTIOptions with decreasing implied volatility
Subscribe for More Information
10:14 EDTRMTIRockwell Medical commercial uptake to be 'dismal', says Brean Capital
Subscribe for More Information
10:14 EDTRMTIRockwell Medical retracing earlier gains, levels to watch
The stock remains up by over 5.7%, last at $11.46, but is heading steadily lower from earlier highs. At the current price next support is at $11.24, the session low and then at $11.01. Resistance is at $11.72.
09:19 EDTRMTIOn The Fly: Pre-market Movers
Subscribe for More Information
08:06 EDTRMTIRockwell Medical Triferic approved by FDA
Subscribe for More Information
07:51 EDTRMTIRockwell Medical trading halted, news pending
Note that FDA PDUFA date for Rockwell Medical's Triferic was January 24.
January 23, 2015
11:23 EDTRMTIRockwell Medical volatility elevated into PDUFA
Subscribe for More Information
08:56 EDTRMTIFDA PDUFA Date for Rockwell Medical's Triferic is January 24, 2015
08:35 EDTRMTIRockwell Medical a buy ahead of PDUFA tomorrow, says Summer Street
Summer Street says it would be a buyer of Rockwell Medical shares ahead of tomorrow's FDA action date for Triferic. The firm sees an "excellent" chance of approval and believes Rockwell could be well into labeling discussions with the FDA. It has a Buy rating on the stock with a $25 price target.
January 22, 2015
07:15 EDTATHXAthersys announces GBP 2M grant to support Phase 2a clinical study of MultiStem
Subscribe for More Information
January 21, 2015
06:15 EDTRMTIRockwell Medical February volatility elevated into PDUFA
Rockwell Medical February call option implied volatility is at 132, March is at 101, May is at 96; compared to its 26-week average of 9- according to Track Data, suggesting large price movement into PDUFA Date for Triferic on January 24.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use